Monopar Therapeutics (NASDAQ:MNPR) Shares Down 4% – Time to Sell?

Monopar Therapeutics Inc. (NASDAQ:MNPR) was down 4% on Wednesday . The company traded as low as $86.03 and last traded at $84.9560. Approximately 19,740 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 57,328 shares. The stock had previously closed at $88.47.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MNPR shares. HC Wainwright set a $105.00 target price on Monopar Therapeutics and gave the company a “buy” rating in a research note on Monday, September 29th. Jones Trading raised shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 10th. BTIG Research boosted their target price on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Wednesday, October 8th. Finally, Leerink Partnrs upgraded shares of Monopar Therapeutics to a “strong-buy” rating in a report on Monday, November 10th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $106.20.

Monopar Therapeutics Trading Down 2.4%

The business has a 50-day moving average price of $83.29 and a 200 day moving average price of $53.70. The stock has a market capitalization of $576.62 million, a P/E ratio of -25.04 and a beta of 1.35.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, sell-side analysts predict that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the transaction, the insider owned 272,026 shares of the company’s stock, valued at approximately $17,303,573.86. This trade represents a 66.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors have recently modified their holdings of MNPR. Russell Investments Group Ltd. purchased a new stake in Monopar Therapeutics during the 3rd quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey bought a new position in Monopar Therapeutics during the second quarter valued at $34,000. AlphaQuest LLC purchased a new stake in shares of Monopar Therapeutics in the first quarter valued at $44,000. BNP Paribas Financial Markets lifted its holdings in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.